ESPE Abstracts

Background: Thyroid dysfunction may predispose to imbalanced body composition.Objective and hypotheses: The aim of the study is to evaluate bone, muscle and fat mass in teenagers with congenital hypothyroidism and correlate their bone profile with laboratory parameters, in an effort to offer more effective lifestyle counselling.Method: Adolescents diagnosed with congenital hypothyroidism through neonatal screening underwent thoroug...

Background: The Spexin gene is considered the most dysregulated in obese human fat with an almost complete absence of expression in obese human fat in comparison with non-obese fat tissues. Limited data from human and animal studies suggest that the novel peptide spexin may potentially impact food intake, weight regulation and body adiposity.Objective: The aim of this study was to compare serum spexin concentrations betw...

Background: Osteogenesis imperfecta (OI) due to COL1A1 and COL1A2 mutations is the most common cause of primary osteoporosis.Case presentation: We present a 10-year-old girl with a history of skeletal fragility, starting in the perinatal period. Her parents are not consanguineous and there is no family history of early osteoporosis. To date, she has sustained nineteen low-energy, long bone fractures and she has skeletal deformities (leg length discrepanc...

Background: Polycystic ovary syndrome (PCOS) is a complex endocrine genetic disorder, which is associated with increased metabolic and cardiovascular morbidity. Vitamin D or omega-3 fatty acids supplementation may alleviate the metabolic and reproductive complications of PCOS.Objective and hypotheses: To compare clinical, psychometric, biochemical, endocrine, bone and sonographic markers in vitamin D sufficient adolescents with PCOS, pre- and post- 6 mon...

Background: Sclerostin is an inhibitor of the Wnt/b-catenin bone metabolic pathway. Increased sclerostin levels and reduced bone mineral density (BMD) have been documented in adult patients with diabetes mellitus (DM), predominantly in those with T2DM. No relevant data exist on childhood T1DM.Objective and hypotheses: Our aim was to study plasma sclerostin concentration in children and adolescents with T1DM and controls and to correlate sclerostin levels...

Background: Several bone metabolic pathways seem to be disrupted in patients with type 1 diabetes mellitus (T1DM), leading to reduced bone mass.Objective and hypotheses: Our aim was to study bone metabolism markers in children and adolescents with T1DM and their correlation with bone mineral density (BMD).Method: We evaluated 40 patients (mean±S.D. age 13.04±3.53 years, mean±S.D. T1DM du...

Background: Disruption of many bone metabolic pathways and reduced bone mass are associated with diabetes mellitus. Increased fracture risk and elevated Dickkopf-1 and sclerostin levels, which are inhibitors of Wnt/β-catenin pathway, have been found in adult T2DM patients, but no relevant data exist on childhood T1DM.Objective and hypotheses: We aimed at studying plasma Dickkopf-1 and sclerostin concentration in children and adolescents with T1DM an...

Introduction: Intravenously given bisphosphonates are the treatment of choice for pediatric osteoporosis. As bone resorption is an essential part of the normal endochondral ossification process, there were concerns on the possible negative impact of bisphosphonates on longitudinal growth during childhood. The aim of this study is to report the impact of zoledronic acid (ZA) on height in pediatric patients with primary osteoporosis.<stron...

Background: X-linked hypophosphatemic rickets (XLH) is a relatively rare chronic bone metabolism disorder, caused by mutations in the X chromosome's PHEX gene. Fibroblast growth factor 23 (FGF23) levels rise, and bone metabolism is affected. The monoclonal antibody burosumab represents a novel therapeutic strategy for managing XLH, targeting the pathophysiology of the disorder. We present our experience of two XLH-diagnosed pediatric patients treated with...

Background: Allogeneic hematopoietic stem cell transplantation (HSCT) has emerged as an increasingly successful option to cure a variety of malignant disorders in children. Children benefit from improved survival; however, HSCT is associated with numerous acute and long-term toxicities. Osteoporosis is a well described, late effect of allogeneic HSCT, associated with corticosteroid treatment and patients exposed to cumulative doses >9000 mg/m2 of prednisone...